# Autonomics and Orthostatic Hypotension

Leonard Chiu

---

## Background

- Orthostatic Hypotension: SBP ↓ \> 20 mmHg, DBP ↓ \> 10 mmHg), or HR
    Increase \> 30 within 3 min of standing up or head-up tilt to 60% on
    a tilt table
- Etiologies: Neurogenic OH (nOH) vs non-neurogenic OH
- nOH associated with autonomic failure
    - Blunted tachycardia during hypotension characteristic of
        autonomic failure
    - nOH: If HR rise is \<15
    - nOH also associated with periods of high BP (supine
        hypertension)
    - Ex: Neurodegenerative disease, neuropathy (diabetes, amyloid,
        paraneoplastic, etc)
- Other causes: volume depletion (most common), medications
    (diuretics, alpha-1 blockers, BB, etc), pump failure (severe AS,
    arrhythmia)

## Evaluation

- Orthostatic vitals signs (checking supine, sitting, and standing
    with 5-minute wait in each position)
- Volume status exam
- Labs: CBC, CMP, EKG, TSH, B12, , LFTs,
- Consider SPEP/UPEP, paraneoplastic panel, autonomic function testing
    depending on clinical context
- Autonomic Function Testing: Available at 4:15pm Tues, Wed, Thurs NPO
    4 hours prior
- Hold oral pressors and antihypertensives 12 hours prior

## Management

- Conservative:
- TED hose and abdominal binder for ambulation
- Drink 16oz of fluid 15 min prior to standing
- If they have supine HTN, keep HOB 30-45 degrees at all times
- Add 2.3-4.6g of salt per day to diet (if no contraindications)
- Avoid high temperatures (which cause peripheral vasodilation)
- Supine HTN therapies: transdermal nitroglycerin (preferred);
    minoxidil, hydralazine, or clonidine in select patients

Orthostatic hypotension pharmacologic therapies

<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 22%" />
<col style="width: 28%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Dose</th>
<th>Mechanism</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Fludocortisone (Florinef)</td>
<td><p>0.1mg QD</p>
<p>↑ by 0.1 mg</p>
<p>Max: 0.3 mg QD</p></td>
<td>Mineralocorticoid increase blood volume. Enhances sensitivity to
circulating catecholamines</td>
<td><p>Edema</p>
<p>HTN</p>
<p>HypoK</p>
<p>Do not use in CHF</p></td>
</tr>
<tr class="even">
<td>Midodrine</td>
<td><p>2.5mg TID</p>
<p>↑ by 2.5mg</p>
<p>Up to 10mg TID</p></td>
<td>Peripheral-selective α1 agonist → constricts both aa &amp; vv</td>
<td><p>Supine HTN</p>
<p>Pilomotor reactions</p>
<p>Pruritus</p>
<p>GI upset</p>
<p>Avoid in uncontrolled HTN, urinary retention, heart disease</p></td>
</tr>
<tr class="odd">
<td>Droxidopa</td>
<td><p>100mg</p>
<p>↑ by 100mg</p>
<p>Up to 600mg TID</p></td>
<td>NE precursor → carboxylated to NE. Can cross BBB.</td>
<td>Supine HTN, less than midodrine</td>
</tr>
<tr class="even">
<td>Atomoxetine</td>
<td>10mg or 18mg</td>
<td>SNRI</td>
<td>Do not use w/ glaucoma or MAOI</td>
</tr>
</tbody>
</table>
